Efficacy and safety of pancreatic juice cytology by using synthetic secretin in the diagnosis of pancreatic ductal adenocarcinoma

2018 ◽  
Vol 30 (6) ◽  
pp. 771-776 ◽  
Author(s):  
Yohei Takeda ◽  
Kazuya Matsumoto ◽  
Hiroki Kurumi ◽  
Hiroki Koda ◽  
Taro Yamashita ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Efficacy And Safety ◽  
Pancreatic Juice Cytology

The Efficacy and Safety of Pancreatic Juice Cytology by Using Synthetic Secretin in the Diagnosis of Pancreatic Ductal Adenocarcinoma

2017 ◽  
Vol 152 (5) ◽  
pp. S493
Author(s):  
Yohei Takeda ◽  
Kazuya Matsumoto ◽  
Hiroki Kurumi ◽  
Hiroki Koda ◽  
Taro Yamashita ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Efficacy And Safety ◽  
Pancreatic Juice Cytology

Diagnostic strategy for early detection of pancreatic ductal adenocarcinoma concomitant with IPMN using ERCP/pancreatic juice cytology

Pancreatology ◽  
2016 ◽  
Vol 16 (4) ◽  
pp. S21
Author(s):  
Takao Ohtsuka ◽  
Yasuhisa Mori ◽  
Yoshihiro Miyasaka ◽  
Kohei Nakata ◽  
Kenoki Ohuchida ◽  
...  
Keyword(s):  
Early Detection ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Diagnostic Strategy ◽  
Pancreatic Juice Cytology

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E

scholarly journals Mutation analysis by deep sequencing of pancreatic juice in patients with pancreatic ductal adenocarcinoma

Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S130
Author(s):  
Man Hung Choi ◽  
Eline Mejlænder-Larsen ◽  
Sophia Manueldas ◽  
Khadija El Jellas ◽  
Solrun J. Steine ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mutation Analysis ◽  
Pancreatic Juice ◽  
Deep Sequencing ◽  
Ductal Adenocarcinoma

scholarly journals Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol Volume 12 ◽  
pp. 12657-12666
Author(s):  
Yuan Zong ◽  
Zhi Peng ◽  
Xicheng Wang ◽  
Ming Lu ◽  
Lin Shen ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Efficacy And Safety ◽  
First Line ◽  
Line Chemotherapy

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E

scholarly journals Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study

2021 ◽  
Vol 13 ◽  
pp. 175883592110582
Author(s):  
Tai-Jan Chiu ◽  
Yung-Yeh Su ◽  
Shih-Hung Yang ◽  
Chung-Pin Li ◽  
Li-Yuan Bai ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Large Population ◽  
Population Based ◽  
Ductal Adenocarcinoma ◽  
Efficacy And Safety ◽  
Population Based Study ◽  
Standard Clinical Practice ◽  
Negative Prognostic Factor ◽  
Liposomal Irinotecan ◽  
Patients Experience

Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficacy and safety of nal-IRI + 5-FU/LV and the association of pre-emptive nal-IRI dosing with treatment outcomes in patients with PDAC. Methods: We retrospectively enrolled a total of 667 consecutive patients with PDAC who received nal-IRI plus 5-FU/LV treatment between August 2018 and November 2020 at 9 medical centers in Taiwan. Patients were allocated into groups according to pre-emptive nal-IRI dosing (⩾75%, 50–74%, <50%) for comparison of treatment efficacy and safety. Results: The median overall survival (OS) and time to treatment failure (TTF) were 5.9 months [95% confidence interval (CI), 5.3–6.5] and 2.8 months (95% CI, 2.6–3.0), respectively. The median OS was 6.5 months (95% CI, 5.7–6.7), 5.0 months (95% CI, 3.4–6.5), and 4.1 months (95% CI, 2.7–5.6), respectively, among the ⩾75%, 50–74%, and <50% pre-emptive nal-IRI dosing groups, whereas the median TTF of the three groups was 3.0 months (95% CI, 2.6–3.4), 2.6 months (95% CI, 2.3–2.9), and 1.9 months (95% CI, 1.6–2.2), respectively. Pre-emptive nal-IRI dosing <50% was an independent negative prognostic factor for OS and TTF in multivariate analyses. The most common severe adverse events were neutropenia (22.9%), anemia (21.1%), and hypokalemia (15.4%). Patients in the <50% pre-emptive nal-IRI dosing group had a significantly lower incidence of neutropenia and non-neutropenic infection than those in the other groups. Conclusion: Our results support the use of nal-IRI + 5-FU/LV as standard clinical practice for treating patients with PDAC based on this large population-based study. Our findings encourage physicians to provide adequate doses of nal-IRI in order to achieve better outcomes without compromising safety profiles.

scholarly journals Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients

BMC Cancer ◽  
2008 ◽  
Vol 8 (1) ◽  
Author(s):  
Mei Tian ◽  
Ya-Zhou Cui ◽  
Guan-Hua Song ◽  
Mei-Juan Zong ◽  
Xiao-Yan Zhou ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Pancreatic Juice ◽  
Proteomic Analysis ◽  
Ductal Adenocarcinoma

The efficacy and safety of pancreatic juice cytology when used with synthetic secretin for the diagnosis of intra-ductal papillary mucinous carcinoma

Pancreatology ◽  
2016 ◽  
Vol 16 (4) ◽  
pp. S70-S71
Author(s):  
Yohei Takeda ◽  
Kazuya Matsumoto ◽  
Hiroki Koda ◽  
Hiroki Kurumi ◽  
Soichiro Kawata ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
Mucinous Carcinoma ◽  
Efficacy And Safety ◽  
Pancreatic Juice Cytology
Sign in / Sign up

Export Citation Format

Share Document